Breaking News
Get 50% Off 0
Get a powerful boost to your portfolio: August's freshest AI-picked stocks
Pick Stocks with AI
Close

Nanexa AB (NANEXA)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
2.1800 +0.0300    +1.40%
16:30:59 - Closed. Currency in SEK
Type:  Equity
Market:  Sweden
ISIN:  SE0007074166 
S/N:  156907747
  • Volume: 170,510
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 2.1100 - 2.2100
Nanexa 2.1800 +0.0300 +1.40%

Nanexa AB Company Profile

 
Get an in-depth profile of Nanexa AB, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryHealthcare Equipment & Supplies
SectorHealthcare
Employees

13

Equity Type

ORD

Nanexa AB (publ), a pharmaceutical company, develops injectable drug products in the Nordic countries, rest of Europe, and North America. The company offers PharmaShell, a drug delivery system based on atomic layer deposition coating technology for controlled release of various types of active pharmaceutical substances. It also develops NEX-22, a glucagon-like peptide-1 analogue liraglutide that has completed Phase I trial for the treatment of type 2 diabetes; NEX-18, a depot drug from azacitidine to treat myelodysplastic syndrome; and NEX-20, a depot drug from lenalidomide for the treatment of multiple myeloma. The company has collaborations with Novo Nordisk and AstraZeneca for the development of pharmaceutical products with active substances. Nanexa AB (publ) was founded in 2007 and is based in Uppsala, Sweden.

Contact Information

Address Virdings Allé 2
Uppsala, 75450
Sweden
Phone 46 18 10 03 00
Fax -

Top Executives

Name Age Since Title
Axel Gaston Glasmacher 62 - Member of Advisory Board - NEX-18 & NEX-20
Uwe Platzbecker - - Member of Advisory Board - NEX-18
Xavier Leleu - - Member of Advisory Board - NEX-20
Richard Davis 52 2022 Independent Director
Christopher Maisel - - Member of Advisory Board - NEX-20
Jose Miguel Torregrosa Diaz - - Member of Advisory Board - NEX-18
Kirsten Gronbaek - - Member of Advisory Board - NEX-18
Hanna Tilus 42 2024 Independent Director
Robert Peter Gale - - Member of Advisory Board - NEX-18
Goran A. Ando 76 2020 Independent Chairman of the Board
Magnus Tobiasson - - Member of Advisory Board - NEX-18
Birgit Stattin Norinder 77 2021 Independent Director
Jakob Dynnes Hansen 70 2023 Independent Director
Emeritus Jan Bolinder - - Member of Advisory Board for NEX-22
Karthik Ramasamy - - Member of Advisory Board - NEX-20
Marie von Lilienfeld-Toal - - Member of Advisory Board - NEX-20
Tim Heise - - Member of Advisory Board for NEX-22
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

NANEXA Comments

Write your thoughts about Nanexa AB
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email